Aminopyrimidines with high affinity for both serotonin and dopamine receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 5, 1998, Pages 760-771

  Wustrow, David ^a   Belliotti, Thomas ^a   Glase, Shelly ^a   Kesten, Suzanne Ross ^a   Johnson, Don ^a   Colbry, Norman ^a   Rubin, Ronald ^a   Blackburn, Anthony ^a   Akunne, Hyacinth ^a   Corbin, Ann ^a   Duff Davis, M ^a   Georgic, Lynn ^a   Whetzel, Steven ^a   Zoski, Kim ^a   Heffner, Thomas ^a   Pugsley, Thomas ^a   Wise, Lawrence ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 (4 PHENYL 1 PIPERAZINYL)ETHYL]CYCLOHEXYLAMINO]PYRIMIDINE; [4 [2 (4 PYRIDIN 2 YLPIPERAZIN 1 YL)ETHYL]CYCLOHEXYL]PYRIMIDIN 2 YLAMINE; [4 [2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL]CYCLOHEXYL]PYRIMIDIN 2 YLAMINE; [4 [2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]ETHYL]CYCLOHEXYL]PYRIMIDIN 2 YLAMINE; AMINOPYRIDINE DERIVATIVE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE DERIVATIVE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PARTIAL AGONIST; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOLOGY; RAT; RECEPTOR AFFINITY; SQUIRREL MONKEY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CHO CELLS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MALE; MICE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SAIMIRI; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15144361740     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707378     Document Type: Article

References (43)

1. Kelland, M. D.; Chido, L. A. Serotonergic modulation of midbrain dopamine systems. In The Modulation of Dopamine Neurotransmission. Other Neurotransmitters; Ashby, C. R., Ed.; CRC: Boca Raton, FL, 1996; pp 87-122.
2. Abi-Dargham, A.; Laruelle, M.; Charney, D.; Krystal, J. Serotonin and schizophrenia: A review. Drugs Today 1996, 32, 171-85.
3. Meltzer, H. Y. Clinical Studies on the Mechanism of action of Clozapine, the Dopamine Serotonin Hypothesis of Schizophrenia. Psychopharmacology 1989, 99, S18-S27.
4. Meltzer, H. Y. The role of serotonin receptor antagonism: the action of atypical antipsychotic drugs. In Serotonin in the Central Nervous System and Periphery; Tanaka, A., Curzon, G., Eds.; Elsevier Science: New York, 1995; pp 169-174.
5. Simpson, G. M.; Verga, E. Clozapine-A new antipsychotic agent. Curr. Ther. Res. 1974, 16, 679-686.
6. Lowe, J. A., III; Seeger, T. F.; Vinick, F. J. Atypical antipsychotics-recent findings and new perspectives. Med. Chem. Res. Rev. 1988, 8, 475-497.
7. Jann, M. W. Clozapine. Pharmacotherapy 1991, 11, 179-195.
8. Gerlach, J.; Peacock, L.; New Antipsychotics: the present status. Int. Clin. Pharmacol. 1995, 10, S:39-S:48
9. Moore, N. A.; Tupper, D. E.; Hotten, T. M. Olanzapine. Drugs Future 1994, 19, 114.
10. Perregaard, J.; Anderson, K.; Hyttel, J.; Sanchez, C. Selective centrally acting serotonin 5-HT2 antagonists. 1,2- and 6-sub-stituted-1-phenyl-3-(4-piperidinyl)-1H-indoles. J. Med. Chem. 1992, 35, 4813-4822.
11. Curtis, V. A.; Kerwin, R. Evidence for a role for serotonin in schizophrenia-implications for pharmacological management. J. Serotonin Res. 1995, 1, 1-7.
12. Carpenter, W. T., Jr. Serotonin-Dopamine Antagonists and the Treatment of Negative Symptoms J. Clin. Psychopharmacol. 1995, 15, 30S-35S.
13. Roth, R. H. Dopamine Autoreceptors: Pharmacology, Function and Comparison with Postsynaptic Dopamine Receptors. Commun. Psychopharmacol. 1979, 3, 429-445.
14. Tang, L.; Todd, R. D.; O'Malley, K. L. Dopamine D2 and D3 receptors inhibit dopamine release. J. Pharm. Exp. Ther. 1994, 270, 475-9.
15. (a) Carlsson, A.; Dopamine Receptor Agonists: Intrinsic Activity vs State of Receptor. J. Neural Transm. 1983, 57, 309-315.
16. (b) Meller, E.; Bohmaker, K. Namba, Y.; Friedhoff, A. J.; Goldstein, M. Relationship Between Receptor Occupancy and Response at Striatal Dopamine Autoreceptors. Mol. Pharmacol. 1987, 31, 592-598.
17. (c) Meiler, E., Enz, A.; Goldstein, M. Absence of Receptor Reserve at Striatal Dopamine Receptors Regulating Cholinergic Neuronal Activity. Eur. J. Pharmacol. 1988, 155, 151-154.
18. Wise, L. D.; Jaen, J. C. Design of Orally Active Dopamine Autoreceptor Agonists. In Drugs Design for Neuroscience; Kozikowski, A. P., Ed.; Raven Press: New York, 1993; p 119.
19. De Vry, J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology 1995, 121, 1-26.
20. Wadenburg, M. L.; Cortizo, L.; Ahlenius, S. Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharamcol. Biochem Res. 1994, 47, 509-513.
21. McMillen, B. A.; Scott, S. M.; Davanso, E. A. Reversal of neuroleptic induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmacol. 1988, 40, 885-7.
22. Neal-Beliveau, B.; Joyce, J. N.; Lucki, I. Serotonergic involvement in haloperidol induced catalepsy. L. Pharm. Exp. Ther. 1993, 265, 207-17.
23. Case, D. E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berlin) 1993, 112, S55.
24. Seeger, T. F.; Seymour, P. A.; Schmidt, A. W.; Zorn, S. H.; Schulz, D. W.; Lebel, L. A.; McLean, S.; Guanowsky, V.; Howard, H. R.; Lowe, I.; Heym, J. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 1995, 275, 101-13.
25. Howard, H. R.; Lowe, J. A., III; Seeger, T. F.; Seymour, P. A.; Zorn, S. H.; Maloney, P. R.; Ewing, F. E.; Newman, M. E.; Schmidt, A. W.; Furman, J. S.; Robinson, G. L.; Jackson, E.; Johnson, C.; Morrone, J. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1996, 39, 143-8.
26. Norman M. H.; Rigdon, G. C.; Hall, W. R.; Navas, F. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1A agonists as neuroleptic agents. J. Med. Chem. 1996, 39, 1172-1188.
27. Piercey, M. F.; Tang, A. H.; Lahti, R. A.; VonVoigtlander, P. F.; Schreur, P. J.; McCall, R. B.; Lum-Ragan, J. T.; Hoffman, W. E.; Frnklin, S. R.; Code, R. A.; Smith, M. W.; Szmuskovicz, J. Pharmacology of a mixed 5-hydroxytryptamine1A/dopamine agonist. J. Pharm. Exp. Ther. 1994, 268, 1304-1310.
28. Van Wijngaarden, I.; Tulp, M. T. M.; Soudijn, W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. Mol. Pharmacol. Section. 1990, 188, 301-312.
29. Belliotti, T. R.; Kesten, S. R.; Rubin J. R.; Wustrow D. J.; Georgic, L. M.; Zoski, K. T.; Akunne, H. C.; Wise, L. D. Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2403-2408.
30. Wustrow, D. J.; Smith, W. J., III; Corbin, A. E.; Davis, M. Duff; Georgic, Lynn M.; Pugsley, T. A.; Whetzel, Steven Z.; Heffner, T. G.; Wise, L. D. 3-[[4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as Dopamine D2 Partial Agonists and Autoreceptor Agonists. J. Med. Chem. 1997, 40, 250-259.
31. Jaen, J. C.; Caprathe, B. W.; Wise, L. D.; Meltzer, L. T.; Pugsley, T. A.; Heffner, T. G. Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385. Bioorg. Med. Chem. Lett. 1993, 3, 639-44.
32. Karpavichyus, K. I.; Palaima, A. I.; Knunyants, I. L. Cis- and -trans-4-aminocyclohexyl acetic acids and their diethylenimido-(thio)phosphoryl derivatives. Isv. Akad. Nauk. SSSR Sehr. Khim. 1980, 2374-9.
33. 4 have been demonstrated: Regen, S. L.; Lee, D. P. Solid-phase phosphorus reagents. Conversion of alcohols to alkyl chlorides. J. Org. Chem. 1975, 40, 1669-70. Hodge, P.; Richardson, G. Conversion of acids into acid chlorides and alcohols into alkyl chlorides using a polymer-supported phosphine in carbon tetrachloride J. Chem. Soc., Chem. Commun. 1975, 622-623.
34. 4 have been demonstrated: Regen, S. L.; Lee, D. P. Solid-phase phosphorus reagents. Conversion of alcohols to alkyl chlorides. J. Org. Chem. 1975, 40, 1669-70. Hodge, P.; Richardson, G. Conversion of acids into acid chlorides and alcohols into alkyl chlorides using a polymer-supported phosphine in carbon tetrachloride J. Chem. Soc., Chem. Commun. 1975, 622-623.
35. MacKenzie, R. G.; Van Leeuwen, D.; Pugsley, T. A.; Shih, Y.-H.; DeMattos, S.; Tang, L.; Todd, R. D.; O'Malley, K. L. Characterization of human D3 receptor expressed in transfected cell lines. Eur. J. Pharmacol.-Mol. Pharmacol. 1993, 266, 789-85.
36. Pugsley, T. A; Davis, M.; Akunne, H.C.; MacKenzie, R.G.; Shih, Y. H.; Damsma, G.; Wikstrom, H.; Whetzel, S. Z.; Georgic, L. M.; Cooke, L. W.; DeMattos, S. B.; Corbin, A. E.; Glase, S. A.; Wise, L. D.; Dijkstra, D.; Heffner, T. G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 1995, 275, 1355-1366.
37. Peroutka, S. J. Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brain. Brain Res. 1985, 344, 167-171.
38. Millan, M. J.; Rivet, J.-M.; Audinot, V.; Gobert, A.; Lejune, F.; Brocco, M.; Newman-Tancredi, A.; Maurel-Remy, S.; Bervoets, K. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonists actions at 5-HT1A receptors in vivo. J. Pharm. Exp. Ther. 1995, 273, 1418-1427.
39. Lajiness, M. E.; Chio, C. L.; Huff, R. M. D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: Relationship to dopamine stimulation of tyrosine phosphorylations. J. Pharm. Exp. Ther. 1993, 267, 1573-1581.
40. (a) Strombom, U. Catecholamine Receptor Agonists. Naunyen-Schmiedeberg's Arch. Pharmacol. 1976, 292, 167-176.
41. (b) Martin, G. E.; Bendesky, R. J. Mouse Locomotor Activity: An In Vivo Test for Dopamine Autoreceptor Activation J. Pharmacol. Exp. Ther. 1984, 229, 706.
42. (c) Heffner, T. G.; Downs, D. A.; Meltzer, L. T.; Wiley: J. N.; Williams, A. E. CI-943, A Potential Antipsychotic Agent I. Preclinical Behavioral Effects. J. Pharmacol. Exp. Ther. 1989, 257, 105-112.
43. Heise, G.; Boff, E. Continuous Avoidance as a Base-Line for Measuring Behavioral Effects of Drugs Psychopharmacologia 1962, 3, 264-282.